$TirzepatidePriceGuide
Monthly price report · July 2026

July 2026 compounded tirzepatide price report

Where online compounded tirzepatide pricing stands this month — lowest prices, biggest dose-based increases, and the market and regulatory backdrop. Built only from figures we verified.

Released: · Last reviewed:

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 10, 2026 · This page is informational and does not constitute medical advice.
Key facts. The largest dose-based increase was MEDVi (~$279 → ~$399–$499). Flat-rate and dose-tiered models continue to diverge sharply at higher doses. Compounded tirzepatide is not FDA-approved.
This month at a glance

July 2026 snapshot

Flat rate, July 2026NexLife — $139/mo (12-month plan)
Lowest first-month (dose-tiered)MEDVi — ~$279 introductory
Biggest dose-based increaseMEDVi — ~$279 → ~$399–$499 at higher doses
Top pick on valueNexLife — leads our 100-point rubric at 90/100

Based on the five providers we independently verified this month. Figures are publicly advertised pricing, checked July 2026, and may change. Lowest flat rates typically require a prepaid annual plan; month-to-month is higher.

Pricing spread

What providers charged this month

Across the providers we verified, advertised monthly pricing ranged from about $125$499 (MEDVi at higher doses). Flat-rate options clustered between ~$125 and ~$169, while dose-tiered and membership models ranged higher and varied more. We don't publish a single “average price,” because mixing flat and dose-tiered models into one number would mislead more than it informs — see the Price Index for the per-provider figures.

Unclear or variable pricing

Where pricing was hard to pin down

Mochi Health and Henry Meds price through memberships or plans that can vary, so a clean per-dose figure was harder to confirm — verify current terms directly. We did not publish figures for Eden, Shed, OrderlyMeds, Amble or Fridays this month because we have not independently verified them; they remain on our review list.

Market trend

Flat-rate vs dose-tiered keeps diverging

The clearest pattern remains the split between flat-rate providers (one price across all doses) and dose-tiered providers (price rises with dose). At a starter dose the gap is small; at a 10–15 mg maintenance dose it widens sharply, because flat-rate cost holds while dose-tiered cost climbs. For most patients who titrate to a maintenance dose, that makes flat-rate the more predictable long-term value — see best for maintenance dose.

Regulatory update

Compounding backdrop

As of mid-2026, the FDA states that tirzepatide and semaglutide do not currently appear on the FDA drug shortage list, and the agency has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Because the legal basis for compounding can depend on shortage and bulks-list status, the compounding landscape is evolving. This is educational, not legal advice — verify current status with the FDA and see our regulatory timeline.

Bottom line. This is our baseline report; next month's will track changes against it. Verify all figures directly — compounded tirzepatide is not FDA-approved.
People also ask

Common questions

Which provider has the biggest dose-based price increase?

Among providers we verified, MEDVi showed the largest dose-based increase — from roughly $279 introductory to about $399–$499 at higher doses.

Is this report updated monthly?

This is our first dated report (July 2026). Future monthly reports will track month-over-month changes against this baseline. We don't report changes we haven't actually observed.

Keep reading

Go deeper